Cann Group Limited has raised $750,000 through a convertible note agreement with Obsidian Global, aiming to strengthen its working capital and move towards EBITDA positivity.
- Raised $750,000 via convertible securities agreement with Obsidian Global
- Convertible note matures in 18 months with variable conversion pricing
- Potential issuance of 25 million options subject to shareholder approval
- Maximum share issuance capped at 195 million without further shareholder consent
- Funds intended to support achieving EBITDA positive status
Funding for Growth
Cann Group Limited (ASX:CAN), a key player in the Australian medicinal cannabis sector, has announced a $750,000 capital raise through a convertible securities agreement with Obsidian Global GP, LLC. This injection of funds is designed to bolster the company’s working capital as it strives to reach a critical financial milestone: becoming EBITDA positive.
Terms of the Convertible Note
The convertible note has an 18-month maturity period and carries no coupon, reflecting a cost-effective funding approach. The conversion price is variable, set at the lower of 92% of the average of the lowest three daily volume-weighted average prices (VWAP) over a 15-day period before conversion notice or a fixed premium price of $0.015 per share. In the event of default, a more favourable conversion price applies, potentially diluting existing shareholders but providing protection to the investor.
Importantly, the agreement caps the maximum number of shares that can be issued without shareholder approval at 195 million, signalling the company’s awareness of dilution risks and its commitment to maintaining governance standards.
Options and Shareholder Approval
As part of the deal, Cann Group must seek shareholder approval to issue 25 million options to Obsidian, exercisable at $0.015 per option and expiring two years after issuance. Should shareholders reject this, the company will instead pay $50,000 in cash to Obsidian. This conditional structure underscores the delicate balance between securing funding and managing shareholder interests.
Strategic Implications
The capital raise comes at a pivotal time for Cann Group, which operates advanced cultivation and manufacturing facilities in Victoria and holds proprietary capsule technology through its Satipharm subsidiary. The fresh capital will help sustain operations and support the company’s growth trajectory in a competitive and evolving medicinal cannabis market.
While the convertible note provides immediate liquidity, the potential for share dilution and the need for shareholder approval on options issuance will be closely watched by investors. How Cann balances these factors will be critical in shaping market confidence and its path to profitability.
Bottom Line?
Cann Group’s latest funding move sets the stage for its next growth phase but raises questions about future shareholder dilution and strategic execution.
Questions in the middle?
- Will shareholders approve the issuance of 25 million options to Obsidian?
- How might the variable conversion price impact Cann Group’s share price and dilution risk?
- What are Cann Group’s plans to achieve EBITDA positivity within the convertible note’s 18-month term?